Bora CDMO Bora CDMO

X

Find ABX196 manufacturers, exporters & distributors on PharmaCompass

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

0

US DMFs Filed

US DMFs Filed

0

CEP/COS Certifications

CEP/COS Certifications

0

JDMFs Filed

JDMFs Filed

0

Other Certificates

Other Certificates

0

Other Suppliers

Other Suppliers

0

API REF. PRICE (USD / KG)

0

INTERMEDIATES

0

DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Uploaded Dossiers

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

0

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

ABX196
Also known as: Abx196, Abx-196, Pbs 96, 1161877-58-2, Unii-soi87f7gn2, Pbs96
Molecular Formula
C50H98N2O9
Molecular Weight
871.3  g/mol
InChI Key
VITDDUXZOHEQMU-BYSUZVQFSA-N
FDA UNII
SOI87F7GN2

iNKT Cell Agonist ABX196 is a synthetic glycolipid agonist for natural killer T-cells (NKTs) expressing an invariant (alpha, beta) T-cell receptor (iNKTs), with potential immunomodulating and antineoplastic activities. Upon infusion of the iNKT cell agonist ABX196, this agent targets and binds to iNKTs, thereby activating iNKTs. In turn, iNKTs recognize CD1d-restricted lipid ligands, which are expressed on certain tumor cells, and secrete large amounts of various cytokines. This may activate the immune system against tumor cells. Additionally, iNKTs directly target and lyse tumor cells.
1 2D Structure

ABX196

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
N-[(2S,3S,4R)-1-[(2S,3R,4S,5R,6R)-6-(acetamidomethyl)-3,4,5-trihydroxyoxan-2-yl]oxy-3,4-dihydroxyoctadecan-2-yl]tetracosanamide
2.1.2 InChI
InChI=1S/C50H98N2O9/c1-4-6-8-10-12-14-16-18-19-20-21-22-23-24-25-26-28-30-32-34-36-38-45(55)52-42(40-60-50-49(59)48(58)47(57)44(61-50)39-51-41(3)53)46(56)43(54)37-35-33-31-29-27-17-15-13-11-9-7-5-2/h42-44,46-50,54,56-59H,4-40H2,1-3H3,(H,51,53)(H,52,55)/t42-,43+,44+,46-,47-,48-,49+,50-/m0/s1
2.1.3 InChI Key
VITDDUXZOHEQMU-BYSUZVQFSA-N
2.1.4 Canonical SMILES
CCCCCCCCCCCCCCCCCCCCCCCC(=O)NC(COC1C(C(C(C(O1)CNC(=O)C)O)O)O)C(C(CCCCCCCCCCCCCC)O)O
2.1.5 Isomeric SMILES
CCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO[C@@H]1[C@@H]([C@H]([C@H]([C@H](O1)CNC(=O)C)O)O)O)[C@@H]([C@@H](CCCCCCCCCCCCCC)O)O
2.2 Other Identifiers
2.2.1 UNII
SOI87F7GN2
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Abx196

2.3.2 Depositor-Supplied Synonyms

1. Abx196

2. Abx-196

3. Pbs 96

4. 1161877-58-2

5. Unii-soi87f7gn2

6. Pbs96

7. Abx-196 [who-dd]

8. Chembl4594427

9. N-((1s,2s,3r)-1-(((6-(acetylamino)-6-deoxy-.alpha.-d-galactopyranosyl)oxy)methyl)-2,3-dihydroxyheptadecyl)tetracosanamide

10. N-((1s,2s,3r)-1-(((6-(acetylamino)-6-deoxy-alpha-d-galactopyranosyl)oxy)methyl)-2,3-dihydroxyheptadecyl)tetracosanamide

11. Tetracosanamide, N-((1s,2s,3r)-1-(((6-(acetylamino)-6-deoxy-.alpha.-d-galactopyranosyl)oxy)methyl)-2,3-dihydroxyheptadecyl)-

12. Tetracosanamide, N-((1s,2s,3r)-1-(((6-(acetylamino)-6-deoxy-alpha-d-galactopyranosyl)oxy)methyl)-2,3-dihydroxyheptadecyl)-

2.4 Create Date
2009-07-15
3 Chemical and Physical Properties
Molecular Weight 871.3 g/mol
Molecular Formula C50H98N2O9
XLogP315
Hydrogen Bond Donor Count7
Hydrogen Bond Acceptor Count9
Rotatable Bond Count43
Exact Mass870.72723271 g/mol
Monoisotopic Mass870.72723271 g/mol
Topological Polar Surface Area178 Ų
Heavy Atom Count61
Formal Charge0
Complexity1010
Isotope Atom Count0
Defined Atom Stereocenter Count8
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY